{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"45","value":"4.5"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"57","value":"6.4"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"80","value":"9.2"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"68","value":"11.5"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"52","value":"11.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1597"},{"groupId":"OG001","value":"575"},{"groupId":"OG002","value":"390"},{"groupId":"OG003","value":"227"},{"groupId":"OG004","value":"77"}],"units":"Participants"}],"description":"Data was analyzed for participants with and without stem cell transplant for all enrolled population, included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data.","dispersionType":"Full Range","groups":[{"description":"The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG000","title":"1st Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG001","title":"2nd Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG002","title":"3rd Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG003","title":"4th Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in \\>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG004","title":">4th Line of Therapy"}],"paramType":"MEDIAN","populationDescription":"All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. Overall number analyzed are the number of participants with data available for analyses. The data is reported as per the known line of therapies.","reportingStatus":"POSTED","timeFrame":"Baseline up to 5 years","title":"Duration of Treatment for Participants With and Without Stem Cell Transplant","type":"PRIMARY","unitOfMeasure":"months"}